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A diseasome cluster-based drug repurposing of soluble
guanylate cyclase activators from smooth muscle relaxation to
direct neuroprotection
Friederike Langhauser1,2, Ana I. Casas3,4, Vu-Thao-Vi Dao3, Emre Guney 5,6, Jörg Menche 7, Eva Geuss1, Pamela W. M. Kleikers3,
Manuela G. López4, Albert-L. Barabási5,6,8,9, Christoph Kleinschnitz1,2 and Harald H. H. W. Schmidt 3
Network medicine utilizes common genetic origins, markers and co-morbidities to uncover mechanistic links between diseases.
These links can be summarized in the diseasome, a comprehensive network of disease–disease relationships and clusters. The
diseasome has been inﬂuential during the past decade, although most of its links are not followed up experimentally. Here, we
investigate a high prevalence unmet medical need cluster of disease phenotypes linked to cyclic GMP. Hitherto, the central cGMP-
forming enzyme, soluble guanylate cyclase (sGC), has been targeted pharmacologically exclusively for smooth muscle modulation
in cardiology and pulmonology. Here, we examine the disease associations of sGC in a non-hypothesis based manner in order to
identify possibly previously unrecognized clinical indications. Surprisingly, we ﬁnd that sGC, is closest linked to neurological
disorders, an application that has so far not been explored clinically. Indeed, when investigating the neurological indication of this
cluster with the highest unmet medical need, ischemic stroke, pre-clinically we ﬁnd that sGC activity is virtually absent post-stroke.
Conversely, a heme-free form of sGC, apo-sGC, was now the predominant isoform suggesting it may be a mechanism-based target
in stroke. Indeed, this repurposing hypothesis could be validated experimentally in vivo as speciﬁc activators of apo-sGC were
directly neuroprotective, reduced infarct size and increased survival. Thus, common mechanism clusters of the diseasome allow
direct drug repurposing across previously unrelated disease phenotypes redeﬁning them in a mechanism-based manner.
Speciﬁcally, our example of repurposing apo-sGC activators for ischemic stroke should be urgently validated clinically as a possible
ﬁrst-in-class neuroprotective therapy.
npj Systems Biology and Applications  (2018) 4:8 ; doi:10.1038/s41540-017-0039-7
INTRODUCTION
Drug discovery and development follows a relatively uniform path
from mechanistic hypothesis, preclinical disease models to clinical
validation. However, in recent years, a string of major drug
developments have failed due to lack of efﬁcacy.1 One reason for
this appears to reside in our current deﬁnitions of ‘disease’, i.e.,
mostly organ-based or by an apparent phenotype or symptom
and not by an underlying mechanisms. However, without a
validated pathomechanism no mechanism-based drugs can be
developed and, therefore, rather surrogate parameters or risk
factors are treated instead. Finding a rational approach towards
mechanism-based disease deﬁnitions may therefore have a
tremendous impact on drug discovery and medicine in general.
Using a data-driven approach, disease–disease networks (dis-
eosome) have been constructed in which diseases are linked
based on common molecular or regulatory mechanisms,2 such as
shared genetic associations,2 protein interactions3,4 or
gene–disease interactions.5 These diseasomes exhibit local
clusters of diseases whose molecular relationships are well
understood, but also unexpected clusters of surprisingly hetero-
geneous diseases.3 Such clustering of disease phenotypes is likely
due to underlying hidden common pathomechanisms. Impor-
tantly, these common mechanism clusters may provide previously
unrecognized molecular deﬁnitions of these phenotypes and at
the same time targets for mechanism-based drug discovery and
repurposing.
Here we test the clinical validity of this approach by focusing on
one cluster of highly prevalent combinations of vascular,
neurological and metabolic disease phenotypes with high unmet
medical need. Genetic evidence points to cGMP signaling as being
part of its underlying pathomechanism.5,6 We then inquire in a
non-hypothesis-based manner using disease–disease networks
based on common genetic origins, common protein interactions
between disease genes, shared disease symptoms and disease
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co-morbidity for possible drug repurposing of cGMP modulators
within this cluster.
RESULTS
Human diseasome and protein interactome of sGC in stroke
The human diseasome provides a framework to pinpoint
connections between seemingly distinct diseases.2 Built by
connecting diseases that share genetic associations, the links in
the diseasome suggest common pathophysiology between
diseases through pleiotropic genes.3,7 Within the diseasome, we
focused on a cluster with disease phenotypes of high prevalence
and unmet medical need. Figure 1a shows an apparently
heterogeneous cluster of several neurological, cardiovascular,
metabolic and respiratory diseases. We then systematically
characterized the therapeutic potential of the diseases inside this
cluster. Five out of twelve phenotypes in this cluster are
therapeutically targeted by drugs modulating cGMP-forming or
cGMP-metabolizing enzymes, including NO donors in myocardial
infarction, sGC stimulators and phosphodiesterase inhibitors
(PDEi) in hypertension, and combined angiotensin II type 1
receptor blocker/neprilysin inhibitor (ARNI) in heart failure (see Fig.
1a for details). Taken together, these common treatments suggest
a prominent role of cGMP signaling in these disease phenotypes,
mostly targeting the NO-responsive sGC.6 All drugs currently
targeting cGMP clinically—NO donors, sGC stimulators and sGC
activators—have almost exclusively cardio-pulmonary indications8
such as coronary artery disease,9 hypertensive crisis10 and
pulmonary hypertension,11 although some of them are currently
being tested in other diseases such as cystic ﬁbrosis
(NCT02170025), systemic scleroderma (NCT02283762)5 and animal
models of kidney diseases.12
To systematically validate and quantify the relationships
between these diseases, we evaluated the importance of (i)
common genes, (ii) protein interactions, (iii) shared symptoms, and
(iv) co-morbidity patterns among all disease pairs in this cluster
(Fig. 1c–f, see Methods for details). To identify disease pairs that
are related to each other, we integrated disease gene, protein
interaction, disease symptom and comorbidity information from
various sources3,14,13, and we generated updated diseasomes
connecting the diseases in the cluster mentioned above. In the
updated diseasomes, two diseases were connected based on the
existence of common disease-associated genes as well as whether
these genes were highly connected with each other in the
interactome. To assess the connectedness of the disease genes,
we checked the number of interactions connecting the genes
from one disease to the genes in the other disease and compared
it to the number of interactions one would observe between
randomly selected gene pairs (see Methods for details). We also
built the co-morbidity and symptoms- based diseasomes in which
two diseases were connected by their comorbidity and the
symptoms they share, respectively. We found that indeed the
diseasomes created using different data sources such as gene
overlap, interactions connecting disease genes, symptom similar-
ity and comorbidity complemented each other (Supplementary
Table S1) and a subset of the diseases within these diseasomes
exhibited substantial relations to one another across all molecular
and phenotypic qualities. We observed that, in addition to
common genetic origins highlighted by shared gene and
interaction based networks, stroke played central role, connecting
various metabolic, cardiovascular and neurological diseases in the
symptom and co-morbidity based networks (Table S2A–D).
Indeed, stroke was either the most central or one of the top
connected nodes in these disease–disease networks and had the
highest degree centrality when the degree of the diseases was
averaged over all networks (Table 1).
To elucidate whether sGC might be related to stroke or other
disease phenotypes within this cluster, we determined the
interactome-based proximity14 of the proteins within the sGC
complex to the proteins associated with major common diseases.
Surprisingly, the network-based analysis identiﬁed sGC not only as
a promising target in non-smooth muscle but suggested that its
main mechanism-based indication should be in neurological
diseases. Of these, vision disorders, ataxia and, again, stroke stood
out. Previously, only very few observations had pointed in that
direction without being clinically exploited, neither in ataxia nor
retinitis pigmentosa.15 All three known subunits of heterodimeric
sGC (alpha-1, alpha-2, and beta-1) were signiﬁcantly close to
genes known to be involved in stroke (Table 2), leading to a joint
z-score of −2.70 but only one report had linked a knock-out of the
sGC alpha-1 subunit to impaired vascular smooth muscle reactivity
and larger ischemic infarcts.7 However, the ﬁnding of a phenotype
in ischemic stroke by knocking out a vasodilatory enzyme such as
sGC is not necessarily a lead. In fact, knocking out any vasodilatory
gene or overexpressing a vasoconstrictive gene will have that
effect. Moreover, mice with a deletion of either the sGCalpha-1 or
beta-1 gene are hypertensive16 and any hypertensive mouse will
show a higher susceptibility to a worsened outcome in experi-
mental stroke; however, at the same time we know that all tested
anti-hypertensives were unsuccessful or dangerous in stroke
therapy.17 Finally, NO, the speciﬁc stimulator of sGC, is toxic in
stroke18 precluding its use and sGC as a therapeutic target.
Nevertheless, since ischemic stroke is the second cause of death
in industrialized countries and the ﬁrst leading cause of disability
and because of our systems-level support for this neurological11
indication, we investigated this possible association and sGC
drug repurposing opportunity. Moreover, despite this high
medical and socio-economical need, no neuroprotective drug is
commercially available and close to 85% of patients have no
therapeutic option.
sGC activity and protein levels in ischemic stroke
We examined whether upon ischemic stroke, any abnormalities in
sGC become apparent that could suggest sGC as a mechanism-
based target. In order to adhere to the quality criteria of pre-
clinical stroke research (Stroke Treatment Academic Industry
Roundtable (STAIR)) recommendations, we used the most
accepted model of transient middle cerebral artery occlusion
(tMCAO) in mice of different age and gender (Fig. 2a). We
analyzed the acute phase of ischemic stroke, because many
consequences of stroke (e.g., infarct volume, blood-brain barrier
disruption, neurological deﬁcits, cell death) can already be
observed at 24 h post-ischemia. We ﬁnd that 24 h after onset of
tMCAO, sGC alpha but not beta protein levels were signiﬁcantly
reduced in homogenates of stroked vs. non-stroked mouse brains
(Fig. 2b). sGC is broadly distributed in different brain structures
such us telencephalon, thalamus, hypothalamus being expressed
mainly in neurons, glial and endothelial cells of the brain
microvasculature.19,20 These ﬁndings are also conserved in human
brain tissue based on The Human Protein Atlas.
Surprisingly, the remaining sGC protein was not responsive to
NO (Fig. 2c), arguing against sGC being a target. This observation
and selective reduction of sGC alpha was reminiscent of an
oxidative stress-mediated mechanism21 favouring the appearance
of a different isozyme, heme-free apo-sGC, which is unresponsive
to NO and prone to degradation.22 Thus rather than sGC (as
suggested by sGC alpha-1 knock out7) but apo-sGC appeared to
be a possible pathomechanism and pharmacological target.
Indeed, speciﬁc apo-sGC activator compounds are available,
which bind to the empty heme pocket of apo-sGC23 to elevate
cGMP under disease conditions.24
In agreement with a mechanism-based role of apo-sGC, post-
stroke apo-sGC activation was fully preserved and even slightly
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increased. The net resulted of these stroke-induced changes was
therefore a dramatic shift of the sGC/apo-sGC ratio resulting in
complete dependence of cerebral cGMP formation on apo-sGC
(Fig. 2d, e).
Infarct size, blood brain barrier disruption and survival upon post-
stroke apo-sGC activation
Having established a mechanism-based appearance of apo-sGC
upon stroke, we next wanted to examine whether post-stroke
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pharmacological targeting of apo-sGC by an apo-sGC activator
may have the potential of a mechanism-based treatment, i.e.
repairing the loss of physiological NO-induced cGMP formation by
generating cGMP through apo-sGC. Stroke pathophysiology leads
to an increase in blood–brain barrier (BBB) permeability allowing
compounds crossing and targeting neuronal signaling pathways.
Since sGC activators (sGCa) can dilate blood vessels and have
hypotensive side-effects, hemodynamically ineffective doses were
chosen for this study. We subjected 8-week-old male and female
C57Bl/6 mice to tMCAO and treated with either of two apo-sGC
activators, BAY58-2667 or BAY60-2770, at two different doses (30
µg/kg and 10 µg/kg of body weight) respectively, either 1 h or 4 h
post-stroke induction. To exclude sex-speciﬁc effects, both 1-year-
old female and male C57Bl/6 mice were also subjected to tMCAO
and treated with BAY60-2770 (10 µg/kg) 1 h post-stroke. To asses
also an alternative stroke model, 8-week-old male and female
C57Bl/6 mice were subjected to permanent occlusion of the MCA
(pMCAO) and treated with BAY60-2770 (10 µg/kg) 1 h post-stroke.
In all cases, infarct volumes were assessed after 24 h by staining
brain sections with 2,3,5-triphenyltetrazolium chloride (TTC).
Consistent with a pathomechanistic role of apo-sGC in stroke,
the BAY60-2770- or 58-2667-treated mice developed signiﬁcantly
smaller brain infarctions on day 1 after tMCAO compared to
controls. No effect was observed in pMCAO suggesting a
reperfusion-dependent effect (Fig. 3a) further arguing against
any vasodilatory component of this effect.
To further analyze the pharmacodynamics of this effects, we
focused on BAY 60-2770, which at the lower dose consistently had
a slightly higher efﬁcacy. Mechanistically, cGMP is suggested to be
involved in the regulation of vascular permeability.25 Therefore,
we analyzed the integrity of the blood-brain barrier after ischemic
stroke measuring the extravasation of the vascular tracer Evans
Blue into the brain parenchyma. Indeed, BAY60-2770 treatment
(10 mg/kg) signiﬁcantly reduced BBB disruption in a dose-
dependent manner (Fig. 3b).
In addition to infarct size reduction and BBB stabilization,
survival is an even more relevant outcome parameter. We
therefore also determined mortality over a time of seven days
after stroke. At day four, 6 of 10 animals in the vehicle group had
died, but just one in the BAY60-2770 treated group. Seven days
after stroke, 9 of 10 mice had died in the control group; in the
BAY60-2770 treated group, only 5 out of 10 (Fig. 3c).
Cerebral blood-ﬂow vs. systemic blood pressure upon apo-sGC
activation
As a point of caution, apo-sGC activators have been shown to be
directly vasoactive.22 Vasoactive drugs (or knock-out models7)
bear the risk of dilating healthy blood vessels more efﬁciently than
those blood vessels affected by the disease condition.26 In
consequence, a paradoxical “steal phenomenon” may be observed
shunting blood from diseased tissue to healthy vascular beds.
Moreover, an additional drop in systemic blood pressure may
lower perfusion pressure15 and affect ischemic reperfusion. We
therefore studied apo-sGC activator treatment over time (during 4
h) to compare the effects on systemic blood pressure vs. relative
regional cerebral blood ﬂow (rCBF) in the territory of the right
middle cerebral artery as measured by Laser Doppler Flowmetry.27
Importantly, no differences in baseline rCBF (100% before
ischemia) nor immediately after ischemia (insertion of the
occluding ﬁlament) were observed, indicating comparable proce-
dural conditions in both groups. Directly after removal of the
ﬁlament, one group of mice was injected with 10 µg/kg BAY60-
2770. From that point on, we observed a higher rCBF in the
treated mice compared to the control group. In the control group
the rCBF rose within the next 2 h after reperfusion (3 h after
Fig. 1 A cGMP-related phenotype cluster within the human diseasome suggests a predominant neurological relevance. a shows the human
disease network2 where nodes represent disease phenotypes that are linked if they share a genetic association. Different colors indicate
different organ systems. Within the network a local cluster contains several diseases phenotypes therapeutically amenable to drugs
modulating cGMP forming or cGMP metabolizing enzymes. This is magniﬁed in b and reveals additional metabolic (blue: DM, diabetes
mellitus; OB, obesity), pulmonary (brown: AB, asthma) and neurological (red: ST, stroke; AD, Alzheimer’s disease; MG, migraine; DE, dementia;
PD, Parkinson’s disease) linked disease phenotypes. For each disease we included in the squares those drugs that are either in the clinic or in
late stage clinical development (sGCa, apo-sGC activators; sGCs, sGC stimulators; NOd, NO donors; ARNi; neprilysin inhibitors; PDEi,
phosphodiesterase inhibitors). Panels indicate common associated genes c, physical interactions between affected proteins d, shared
symptoms e and elevated comorbidity f. When analyzing the interactome of sGC g, its subunits (orange) are signiﬁcantly closer to
neurological diseases (red) than random expectation and surprisingly more distant to cardiovascular applications (dark blue) that current
clinical practice (Table 2)











Stroke 10 10 2 7 7.25
Alzheimer disease 6 9 1 5 5.25
Dementia 6 10 3 0 4.75
Atherosclerosis 3 6 0 8 4.25
Asthma 3 7 1 5 4
Diabetes mellitusa 6 10 0 0 4
Parkinson disease 3 7 2 4 4
Heart Failure 1 4 2 7 3.5
Migraine Disorders 1 7 0 5 3.25
Myocardial Infarction 4 7 2 0 3.25
Hypertension 1 3 1 7 3
Obesity 2 4 0 6 3
a Diabetes mellitus type 2
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MCAO) reaching a maximum of about 80% of the baseline level
followed by a recurrent drop of rCBF at 3 h after reperfusion. In
contrast, in the BAY60-2770 group, rCBF increased steadily until 4
h after ischemia. Of note, rCBF strikingly increased and reached a
level that was nearly threefold higher than baseline (Fig. 3d). No
signiﬁcant inﬂuence of 10 µg/kg BAY60-2770 on systemic blood
pressure was observed (Fig. 3e).
Improved neurological outcome upon post-stroke apo-sGC
activation
Clinically, smaller infarct and survival would be important, but so
would quality of life and/or neurological function in survivors.
Thus, we additionally assessed three independent neuro-
functional parameters both in the adult and middle-aged mouse
model treated 1 h post-stroke, i.e., the elevated body swing
test (Fig. 3f), the four-limb hanging wire test (Fig. 3g), and the Grip
test (Fig. 3h). In the middle-aged model, only the elevated body
swing test and Grip test showed signiﬁcant improvement, while
in the adult model, importantly, all three neuro-functional
outcome parameters were signiﬁcantly improved. Thus, activating
post-stroke elevated apo-sGC reduced infarct volume, increased
survival, and in surviving animals protected neuro-motor
function.
Effects of apo-sGC activation on microglia and early inﬂammation
Upon stroke, both interleukin-1β (IL-1β)28 and tumor necrosis
factor-α (TNF-α),29 are induced early30 in microglia and inﬁltrating
macrophages contributing to neurodegeneration.31–33 To assess
whether these events are also related to apo-sGC, we ﬁrst
assessed microglia activation and inﬁltrating macrophages in
stroked animals with and without treatment with the apo-sGC
activator BAY 60-2770 (10 µg/kg). Indeed, 24 h post-treatment
microglia activation and inﬁltration of macrophages was signiﬁ-
cantly reduced by BAY 60-2770 compared with non-treated
controls (SI Fig. S1). Consistent with this, expression of IL-1β and
TNF-α were signiﬁcantly reduced by BAY 60-2770 treatment 4 h
post-stroke (SI Fig. S2A-B). These data corroborate the key role of
apo-sGC and its pharmacological targeting in stroke.
Direct neuroprotection via cGMP-dependent protein kinase (PKG)/
p-CREB
Since the absence of hypotension and dependence on reperfusion
suggested that apo-sGC activators were acting via a previously
unrecognized direct neuroprotective effect in agreement with the
diseasome guided primary neuronal disease association, we
investigated their direct effects on hypoxia-induced neuronal
apoptosis, a well-established mechanism of tissue damage in
ischemic stroke.34 Indeed, 24 h after stroke onset immunolabeling
of TUNEL and NeuN revealed widespread apoptosis in the vehicle
treated mice. In contrast, the number of apoptotic cells in the
BAY60-2770 treated animals was signiﬁcantly reduced (Fig. 4a).
Moreover, we studied an additional in vitro model free of
functional vascular components, i.e., hippocampal slices that
maintain their morphology and properties of synaptic function
similar to those under in vivo conditions. We simulated an
ischemic stroke and reperfusion scenario by exposing the slices to
a 15 min period of oxygen and glucose deprivation (OGD),
followed by a 2 h period of re-oxygenation (ReOx) in the absence
or presence of the sGC activators, BAY58-2667 (100 nM) or BAY60-
2770 (100 nM). In some experiments, the inhibitor of cGMP-
dependent protein kinase (PKG), KT5823 (60 nM), was added to
either of the apo-sGC activators. When determining hippocampal
cell viability by the MTT assay, both apo-sGC activators were
directly neuroprotective upon OGD. This protection was comple-
tely lost when the PKG inhibitor KT5823 was present (Fig. 4b)
suggesting that both apo-sGC activators exerted their protection
by elevating cGMP and PKG activity.
Since the transcription factor CREB has been described as a key
mechanism of neuronal growth and survival,35 we considered its
involvement as a possible phosphorylation substrate of PKG.36
Indeed, the apo-sGC activator BAY60-2770 signiﬁcantly increased
CREB phosphorylation, an effect that was completely prevented in
presence of the PKG inhibitor, KT5823 (Fig. 4c). Consistent with
this, CREB phosphorylation was signiﬁcantly increased in tMCAO
Table 2. Interactome-based proximity from sGC subunits to various
disease phenotypes
sGC subunita Stroke Disease Zb p-valuec
All Vision disorders −3.405 0.00033
Varicose veins −3.135 0.00086
Esophageal disease −3.001 0.00134
Spinocerebellar ataxias −2.995 0.00137
Asthma −2.787 0.00266
Head and neck neoplasms −2.725 0.00321
* Stroke −2.698 0.00348
Retinitis pigmentosa −2.279 0.01132
Diabetes mellitus type 2 −2.122 0.01691
α-1 Vision disorders −3.711 0.00010
Varicose veins −3.239 0.00060
Esophageal disease −2.959 0.00154
Spinocerebellar ataxias −2.741 0.00307
Head and neck neoplasms −2.529 0.00572
Asthma −2.494 0.00631
* Stroke −2.288 0.01106
Retinitis pigmentosa −1.923 0.02727
Diabetes mellitus type 2 −1.778 0.037678
α-2d Vision disorders −2.383 0.00859
Spinocerebellar ataxias −2.356 0.00923
* Stroke −2.289 0.01105
Varicose veins −2.240 0.01255
Esophageal disease −2.238 0.01263
Asthma −2.217 0.01330
Head and neck neoplasms −2.127 0.01672
Retinitis pigmentosa −2.108 0.01751
X-linked mental retardation −2.080 0.01874
β-1e Vision disorders −2.387 0.00848
* Stroke −2.339 0,00966
Asthma −2.291 0.01097
Varicose veins −2.270 0.01162
Spinocerebellar ataxias −2.266 0.01172
Head and neck neoplasms −2.225 0.01302
Esophageal disease −2.199 0.01394
Retinitis pigmentosa −2.041 0.02062
Diabetes mellitus type 2 −1.931 0.02671
a sGC is an heterodimer requiring both one α and one β subunit
b For each protein and diseases, the proximity quantiﬁes the signiﬁcance of
closeness of the set of proteins to the disease-genes, producing negative z-
scores for protein–disease pairs that are closer in the interactome
compared to random expectation
c The p-value was calculated using the proximity score (z), corresponding
to the probability that a randomly selected protein having the same
degree in the interactome as the protein of interest would be at least as
close to the disease genes than the observed distance in the interactome
d For stroke (annotated as cerebrovascular disease in MeSH), α2-subunit,
which is predominantly expressed in neurons has the third highest score
e The active β1 subunit has the second highest score
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mice treated with BAY60-2770 (Fig. 4d) correlating with its anti-
apoptotic effects in vivo. Taken together, our data suggest that
post-stroke apo-sGC but not sGC is a mechanism-based target and
its activation is directly neuroprotective via PKG-CREB dependent
signaling (Fig. 4e).
DISCUSSION
Here we apply a new approach to disease deﬁnition, target
identiﬁcation and validation. We also provide a top-down drug
repurposing strategy and experimental conﬁrmation of drug
repurposing based on the human diseasomes generated by not
Fig. 2 Decreased sGC expression and activity upon ischemic stroke. We tested the primary role of sGC in stroke in a mouse model of transient
middle cerebral artery occlusion (tMCAO). a Collection of the right brain hemispheres 24 h after tMCAO (stroke) or from control animals (non-
stroke) and subsequent cryo-homogenization in sGC assay buffer. Subsequently, the expression of sGCα and sGCβ subunits were measured by
Western blot b sGC activity as cGMP formation c, d, in the absence or presence of the NO donor, DEA/NO, which stimulates the Fe(II) heme-
containing native sGC, or apo-sGC activator (sGCa), BAY58-2667, which activates the heme-free apo-sGC (see Methods). sGCα expression (n=
5, p< 0,05), in b and NO-Fe(II)sGC activity (n= 5) were signiﬁcantly reduced after stroke. c, d This loss of NO-Fe(II)sGC activity resulted in a near
complete shift in the cGMP response being post-stroke largely dependent on apo-sGC activation (n= 3, p< 0,05). e Loss of heme in the NO-
responsive Fe(II)sGC upon stroke, which may possibly involve ROS formation (19). The resulting heme-free apo-sGC is prone to degradation of
its α subunit.50 cGMP formation can be partially recovered by apo-sGC activation, which binds to the empty heme pocket of apo-sGC opening
up a mechanism-based therapeutic option
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only common genetic origins but also shared protein interactions,
symptom similarity and comorbidity.
Shared gene associations can offer mechanistic insights into
common pathophysiology of seemingly distinct diseases. The
human diseasomes leverages such genetic and clinical common-
alities among diseases, giving rise to key applications from
characterization of disease comorbidities to drug repurposing.3
Unlike previous studies that rely mainly on common genetic
origins, we exploit large-scale disease and interaction data for
hypothesis generation within a cluster of apparently mechan-
istically related cerebro-cardio-metabolic disease phenotypes with
high prevalence and unmet medical needs. Genetic6,7 and
pharmacological5,37,38 evidence had suggested that these are
associated with and deﬁned by (an impairment of) cGMP
Fig. 3 Post-stroke treatment with either of two apo-sGC activators reduces infarct size, prevents blood-brain barrier disruption, improves two
of three neurological outcomes and increases survival in a reperfusion-dependent manner. a 24 h after transient (with reperfusion) but not
permanent (without reperfusion) occlusion of the middle cerebral artery (tMCAO and pMCAO, resp.) infarct size is reduced in mice treated
with BAY58-2667 (30 μg/kg) 1 h post-stroke (n= 10, p< 0,001) and BAY60-2770 (10 μg/kg) 1 h (n= 19, p< 0,001) and 4 h (n= 10, p< 0,001).
Infarct volume was also signiﬁcantly reduced in middle-aged animals treated with BAY60-2770 (10 μg/kg) 1 h post-stroke (n= 8, p< 0,01). b
Mechanistically, BAY60-2770 treatment (5 and 10 μg/kg) reduced blood- brain barrier leakage in a dose dependent manner (n= 10, p<
0,0001). c Apo-sGC activation treatment increased survival as soon as after day 1, which persisted until day 8, when 100% of control mice had
died (n= 10, p< 0.05). d Post-stroke cerebral blood ﬂow was increased in response to BAY60-2770 (n= 5, p< 0.05) while e systemic blood
pressure was not modiﬁed at the chosen dose (10 μg/kg) (n= 4). f–h With respect to the neurological outcome of BAY60-2770 treatment in
surviving mice, the elevated body swing test indicated a signiﬁcant increase for the right swing number/total swing number ratio both in
adult (n= 19, p< 0.01; panel f) and middle-aged mice (n= 8, p< 0.05; panel f ) while signiﬁcantly improved motor outcome after four limb
hanging test was only seen in the adult model (n= 19, p< 0.05, panel g). Similarly, the grip-test was signiﬁcantly improved in both mice
models (n= 19, n= 8, p< 0.05, panel h)
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signaling. Therefore we focused our non-hypothesis-based
approach on the cGMP generating soluble guanylate cyclase,
currently clinically targeted mainly for cardiovascular indications.
Previous studies suggest increased cGMP levels may interact in
modulating hypoxic stimulation of erythropoietin (EPO) produc-
tion.39,40 Likewise, post-stroke treatment with erythropoietin
showed neuroprotective effects in cerebral ischemia41 by reducing
neuroinﬂammation42 and promoting synaptic plasticity.43 There-
fore, pharmacological treatment post-stroke using sGC activators
may also stimulate erythropoietin production leading to a
secondary neuroprotective pathway. However, we believe that a
mechanism-based upstream effector such as sGC having multiple
downstream effectors, such as EPO, direct neuroprotection, and
cytokines, has a higher chance of being therapeutically relevant.
This may also explain why EPO-only therapeutic approaches in
stroke failed eventually in the clinic.44
We combine in silico, in vitro, and in vivo methods and
surprisingly ﬁnd previously not recognized neurological disease
Fig. 4 Both in vitro and in vivo sGC activation is directly neuroprotective in a cGMP-PKG-CREB dependent manner. a Improved outcome in
treated mice (see Fig. 3) was associated with decreased cortical neuronal apoptosis (n= 4, p< 0.001) suggesting a novel neuroprotective
mechanism. b shows an in vitro ischemia model free of vascular and blood-brain-barrier components. After dissection, hippocampal brain
slices were subjected to oxygen and glucose deprivation (OGD)/re-oxygenation (ReOx) in the absence or presence of the sGC activators,
BAY58-2667 or BAY60-2770, with and without the cGMP-dependent protein kinase inhibitor, KT5823.61 Both BAY58-2667 (n= 7, p< 0.05) or
BAY60-2667 (n= 13, p< 0.05) increased cell viability after OGD/Re-Ox. Adding the PKG-inhibitor KT5823 reversed this effect for both BAY58-
2667 (n= 8, p< 0.05) and BAY60-2770 (n= 7, p< 0.05). c BAY60-2770 treatment increased the ratio of the PKG substrate p-CREB/t-CREB upon
OGD/ReOx (n= 8, p< 0.05), an effect was completely prevented in the presence of the PKG-inhibitor KT5823 (n= 4, p< 0.05), suggesting a
neuroprotective link. d Similarly, p-CREB/t-CREB ratio was signiﬁcantly increased in vivo 24 h post-stroke (n= 4, p< 0.05). e Schematic
representation of the suggested neuroprotective signaling events: BAY58-2667/60-2770 speciﬁcally activates the predominant post-stroke
form of sGC (heme-free apo-sGC) and thereby recovers lost sGC-dependent cGMP formation, which leads to CREB phosphorylation and direct
neuroprotection
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phenotypes as the most promising indication for this target.
Moreover, when selecting out of these the indication stroke, we
do not ﬁnd NO-sensitive sGC but a pharmacologically entirely
different isoform, apo-sGC, to be the target. Indeed, using a set of
apo-sGC speciﬁc activator compounds, we observe direct neuro-
protection independent of vascular effects.
Functionally, this led to reduced infarct size, reduced mortality
and improved neurological outcome in surviving animals,
independent of sex and age. Thus apo-sGC activators should be
urgently examined for re-purposing for the high unmet medical
need indication, stroke, and possibly other neurological disease
phenotypes such as vision disorders, spinocerebellar ataxias and
retinitis pigmentosa.15 apo-sGC activator compounds, currently in
phase II clinical development for heart failure,45 a chronic
cardiovascular indication, should be examined in phase IIb/III
acute studies in low non-hypotensive doses in ischemic stroke.
Because of no apparent bleeding risk, therapy may be started
earlier, in the ambulance as soon as a stroke is suspected in a
patient; it may also have a wider time-window than current t-PA
and may be extended to neuroprotection in hemorrhagic stroke
for which no pharmacotherapy is available. This lack of deﬁnitive
clinical proof-of-concept is of course still the major limitation of
our present combined in silico and pre-clinical ﬁndings. Mechan-
istically, PKG-CREB-dependent signaling seemed to mediate these
effects.
On a more general scale, our sequence of in silico diseasomes
cluster-based target identiﬁcation and subsequent in vivo/in vitro
validation may represent an innovative, non-hypothesis driven
approach to drug discovery and repurposing for other unmet
medical needs when classical hypothesis-driven discovery
approaches have resulted in unsatisfactory clinical efﬁcacy. It is
possible to repurpose within a common mechanism cluster one
target—in our case sGC—from one organ system (cardiovascular)
to another (neurological). However, genetic deﬁnition of this
target, i.e., sGC, would have been insufﬁcient as surprisingly a
protein isoform, apo-sGC and speciﬁc activator compounds,
provided the key discovery. It is unclear whether apo-sGC was
derived from sGC (by heme loss) or de novo from incomplete
heme insertion.46
Common molecular mechanisms, such as cGMPopathies,
deﬁning at least partially the present cluster, may be a more
precise and molecular denominator of disease rather than
describing an organ- or symptom-based phenotype and could
lead to an entirely new deﬁnition of disease.47,48 Basing a disease
on an underlying molecular mechanism will by deﬁnition provide
a translational handle, both with respect to diagnostics and




All stroke experiments were performed in accordance with the recently
published ARRIVE guidelines (http://www.nc3rs.org/ARRIVE). An indepen-
dent person not involved in data acquisition and analysis randomly
assigned animals to the operators. We performed surgery and evaluation
of all read-out parameters while being blinded to the experimental groups.
Animals were excluded from end-point analyses (exclusion criteria) if death
occurred within 24 h after MCAO, if subarachnoidal hemorrhage (SAH) or
intracerebral hemorrhage (ICH) occurred (as macroscopically assessed
during brain sampling), or if, 60 min after tMCAO, Bederson scores were =
0. Of the 242 mice subjected to MCAO, 38 mice (15.7%) met at least one of
these exclusion criteria after randomization and were withdrawn from the
study resulting in 204 included mice. The drop-out rates was 22 mice in the
vehicle group vs. 16 mice in the BAY60-2770 treated group. The study
design was deﬁned based on a power animal calculation analysis49 for all
groups involved in the study considering different compounds (BAY58-
2667 and BAY60-2770), doses (30 µg/kg, 10 µg/kg), treatment time-points
(1 h and 4 h post-stroke), age of the animals (adults and middle-aged)
based on mean infarct size, standard deviation a and number of animals
used always comparing vehicle and treatment administration (Table S3).
The study was conducted in accordance with institutional guidelines
(University of Würzburg, Germany) for the use of experimental animals,
and the protocols were approved by governmental authorities (Regierung
von Unterfranken, Würzburg, Germany).
Human interactome analysis
We used an integrated human interactome containing 141,150 experi-
mentally documented physical interactions between 13,329 proteins, as
curated by ref. 3 From the same study, we used 299 diseases deﬁned by
MeSH classiﬁcation and their associated genes that were curated from
OMIM and GWAS databases to identify disease modules within the
interactome. To remove potential redundancy among diseases, we
calculated the Jaccard Index between every pair of diseases using the
genes associated to them and ﬁltered the disease terms that had a Jaccard
Index higher than 0.5 to a disease in the data set, yielding 132 diseases. For
each of the sGC proteins, guanylate cyclase soluble subunit beta-1
(GUCY1B3), guanylate cyclase soluble subunit alpha-2 (GUCY1A2) and
subunit alpha-3 (GUCY1A3), we calculated the minimum shortest path
length to known disease genes for each of the 132 diseases. As control, we
further computed the minimum shortest path lengths from the sGCα
proteins to 1000 randomly chosen genes sets containing the same number
of genes as the respective disease. From the mean and standard deviation
of these random controls we then calculated a z-score, z = (dobserved−<dran-
dom>)/σrandom, to quantify the signiﬁcance of the closeness of the sGCα
proteins to a given disease. We converted z-scores to P-values and then
adjusted the P-values using the Benjamini–Hochberg multiple hypothesis
testing correction method. We set the alpha value for FDR to 25% and
considered any disease with an FDR less than or equal to this value as
signiﬁcantly close to the sGCα protein.
Disease–disease relationships
The four different relationships among the diseases in the cluster depicted
in Fig. 1c–f were obtained as follows: (i) We determined the number of
shared genes (Fig. 1c) from gene-disease association data combined from
ref. 3 to ref. 50 (ii) We computed the number of physical protein interactions
connecting the gene products of the two respective diseases using
interactome data from.3 For every disease pair, we ﬁrst checked the
number of interactions connecting the genes from one disease to the
genes in the other disease (see the Supplemenary Material for the
pseudocode for this procedure). We then compared the number of
observed interactions between disease genes to the number of interac-
tions one would observe between randomly selected gene pairs and used
the normalized score (z-score) to decide whether the disease genes were
more connected to each other compared to random pairs of genes. The
expected distribution of the number of interacting gene pairs was
generated using 1000 randomly chosen pairs of gene sets containing the
same number of genes as the two diseases in consideration. The z-score
was calculated using the mean and standard deviation of this distribution.
Links in Fig. 1d indicate a signiﬁcant number of interacting proteins. (iii) We
extracted disease pairs with high symptom similarity4 (Fig. 1e). Only the
symptoms that had strong support (TF-IDF score > 3.5) in the original data
set were considered in the analysis. (iv) Elevated co-morbidities calculated
from disease pairs reported in insurance claims (Fig. 1f) were taken from
ref. 51 The ICD9 codes provided in the original data set were converted to
MeSH identiﬁers using the mapping provided by Disease Ontology and
only the diseases that could be unambiguously mapped were included in
the analysis. The pairwise disease–disease relationship scores correspond-
ing to the calculated gene and interaction sharing, symptom similarity and
comorbidity are available in Tables S2A-D.
Centrality analysis of diseases in diseasomes
To prioritize the diseases, we generated four diseasomes based on the
disease–disease relationship scores above. We kept only the links that
correspond to non-spurious relationships between diseases by including
disease pairs that shared at least one gene (n > 0); had positive shared
protein interaction score (z > 0); showed symptom similarity (Jaccard index
> 0.5); and are known to be comorbid (relative risk > 1) in the four
diseasomes, respectively. We then calculated degree centrality of each
disease within these diseasomes and averaged the centrality values as the
ﬁnal centrality value of the disease across diseasomes (Table 1). To ensure
that the incompleteness of the interaction data did not have a signiﬁcant
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effect on the ranking of the diseases, we also checked the centrality of the
diseases without using the interactome-based diseasome and found that
stroke remained as the most central disease across the diseasomes (Table
S4). The coverage and average degree of the individual diseasomes are
given in Table S1.
sGC activity
The determination of sGC activity was performed in homogenates of
mouse stroked ipsilateral cortex and basal ganglia vs. non-stroke cortex
and basal ganglia, as previously described.23 Brieﬂy, crude brain
homogenates of stroked and non-stroked C57Bl/6 mice were measured
as the formation of cGMP at 37 C during 10min in a total incubation
volume of 100 μl containing 50mM triethanolamine–HCl (pH 7.4, Sigma), 3
mM MgCl, 3 mM glutathione (Carl Roth), 1 mM 3-isobutyl-1-
methylxanthine (IBMX, Enzo LifeSciences), 100mM zaprinast (Enzo Life-
Sciences), 5 mM creatine phosphate (CalBiochem), 0.25mg/ml creatine
kinase (CalBiochem), and 500mM GTP. The reaction was started by
simultaneous addition of the crude brain homogenates and either DEA/NO
(Enzo LifeSciences) or BAY58-2667 (Adipogene), respectively. After
incubation of each sample (n = 3 each per group) for 10min the reaction
was stopped by boiling for 10min at 95 °C. Thereafter, the amount of
cGMP was subsequently determined by an enzyme immunoassay (ENZO
cGMP EIA kit) using different sample dilutions in the linear range.
In vivo MCAO ischemia model
C57BL/6 mice were subjected to middle cerebral artery occlusion (MCAO)
followed by 24 h of reperfusion. Focal cerebral ischemia was induced by
60min transient middle cerebral artery occlusion (tMCAO) as described in
refs. 52–54 Mice were anesthetized with 2.5% isoﬂurane (Abbott) in a 70%
N2O/30% O2 mixture. Core body temperature was maintained at 37 °C
throughout surgery by using a feedback-controlled heating device.
Following a midline skin incision in the neck, the proximal common
carotid artery and the external carotid artery were ligated and a
standardized silicon rubber-coated 6.0 nylon monoﬁlament (6021; Doccol)
was inserted and advanced via the right internal carotid artery to occlude
the origin of the right MCA. The intraluminal suture was left in situ for 60
min. Then animals were re-anesthetized and the occluding monoﬁlament
was withdrawn to allow for reperfusion. For permanent MCAO (pMCAO)
the occluding ﬁlament was left in situ until sacriﬁcing the animals.54
Operation time per animal did not exceed 10min.
Treatment with apo-sGC activators
BAY60-2270 and BAY 58-2667 were dissolved in a mixture of Transcutol/
Cremophor/water in a ratio of 10/20/70.55 BAY 58-2667 (30 µg/kg), BAY60-
2270 (5 µg/kg or 10 µg/kg) or vehicle (Transcutol/Cremophor/water in a
ratio of 10/20/70) was injected i.v. at the time of reperfusion (immediately
after removal of the ﬁlament) except in one group where BAY 60-2270 was
injected 3 h after removal of the ﬁlament that means 4 h after induction of
tMCAO.
Determination of blood-brain-barrier leakage and brain edema
To determine blood–brain–barrier leakage 100 µl of 2% Evan’s Blue tracer
(Sigma Aldrich) diluted in 0.9% NaCl was i.v. injected 1 h after the induction
of tMCAO. After 24 h mice were sacriﬁced and brains were quickly
removed and cut in 2mm thick coronal sections using a mouse brain slice
matrix (Harvard Apparatus). Brain slices were ﬁxed in 4% PFA at 4 °C for 2 h
in the dark. Then, brain slices were cut into small pieces using a scalpel and
then transferred into Eppendorf tubes. 500 µl Formamid was added to
each tube and incubated for 24 h at 50 °C in the dark. Tubes were
centrifuged for 20min at 16,000 g and 50 µl of the supernatant was
transferred to a 96 well plate. Fluorescence intensity was determined in
duplicates by a microplate ﬂuorescence reader (Fluorosan Ascent, Thermo
Scientiﬁc) with an excitation at 620 nm and emission at 680 nm. The
concentration for each sample was calculated from a standard curve using
linear regression analysis.
Invasive hemodynamics
For the assessment of blood pressure mice were anesthetized with 2.0%
isoﬂurane and catheterized via the right carotid artery with a high-ﬁdelity
1.4 F Millar microtip catheter (Milar Instruments), as described in ref. 56
Hemodynamic data were digitized via a MacLab system (AD Instruments)
connected to an Apple G4 PowerPC computer and analyzed.
Laser Doppler ﬂowmetry
Laser Doppler ﬂowmetry (Moor Instruments) was used to monitor relative
regional cerebral blood ﬂow (rCBF) in the right MCA area.57 For this
procedure, a small incision was made in the skin overlying the temporal
muscle, and a 0.7 mm ﬂexible Laser Doppler probe (model P10) was
positioned perpendicular to the superior portion of the temporal bone (6
mm lateral and 2mm posterior from bregma). This position corresponds to
the core of the ischemic territory. rCBF was measured serially at baseline
(before ischemia), immediately after insertion of the occluding ﬁlament
(ischemia), immediately after removal of the occluding ﬁlament (reperfu-
sion) and again 1 h, 2 h, and 3 h after reperfusion.
Determination of infarct size
After sacriﬁcing the mice, brains were quickly removed and cut in three 2-
mm thick coronal sections using a mouse brain slice matrix (Harvard
Apparatus). The slices were stained for 10min at 37 °C with 2% 2,3,5-
triphenyltetrazolium chloride (TTC; Sigma-Aldrich) in PBS to visualize the
infarctions.58 Indirect, i.e., corrected for brain edema, infarct volumes were
calculated by volumetry (ImageJ software, National Institutes of Health,
USA) according to the following equation: Vindirect (mm
3) = Vinfarct×(1
−(Vih−Vch)/Vch), where the term (Vih−Vch) represents the volume difference
between the ischemic hemisphere and the control hemisphere and
(Vih−Vch)/Vch expresses this difference as a percentage of the control
hemisphere.
Assessment of neuro-functional outcomes
Three different neuro-motor functioning tests were assessed in all mice
groups (male, female, middle-aged) treated 1 h post-ischemia. For the grip
test59 the mouse was placed midway on a string between two supports
and rated as follows: 0, falls off; 1, hangs on to string by one or both fore
paws; 2, as for 1, and attempts to climb on to string; 3, hangs on to string
by one or both fore paws plus one or both hind paws; 4, hangs on to string
by fore and hind paws plus tail wrapped around string; 5, escape (to the
supports). For the elevated body swing test the mice was held ~1 cm from
the base of its tail. Then, it was elevated above the surface in the vertical
axis. A swing was considered whenever the animal moved its head out of
the vertical axis to either the left or the right side (> 10°). To evaluate limb
strength, the four-paw wire hanging test was performed. The mouse was
placed on the center of the wire with a diameter of 8 cm and then the wire
was slowly inverted and placed at 40 cm above a paper towel bedding. The
time until the mouse fell from the wire was recorded, and the maximum
time was set to 120 s.
Staining of activated microglia/macrophages
Cryo-embedded slices were ﬁxed in 4% PFA in PBS. Blocking of epitopes
was achieved by pre-treatment with 5% bovine serum albumin (BSA) in
PBS for 45min to prevent unspeciﬁc binding. Rat anti-mouse CD11b
(microglia/macrophages; MCA711, AbD Serotec) at a dilution of 1:100 in
PBS containing 1% BSA was added overnight at 4 °C. Afterwards, slides
were incubated with a biotinylated anti-rat IgG (BA-4001, Vector
Laboratories) diluted 1:100 in PBS containing 1% BSA for 45min at room
temperature. Following treatment with Avidin/Biotin blocking solution
(Avidin/Biotin Blocking Kit, Sp-2001, Vector Laboratories) to inhibit
endogenous peroxidase activity, the secondary antibody was linked via
streptavidin to a biotinylated peroxidase (POD) according to the
manufacturer’s instructions (Vectorstain ABC Kit, Peroxidase Standard PK-
4000, Vector Laboratories). Antigens were visualized via POD using the
chromogen 3,3′- Diaminobenzidin (DAB) (Kem-En-Tec Diagnostics). For
quantiﬁcation of immune cells identical brain sections (thickness 10 µm) at
the level of the basal ganglia (0.5 mm anterior from bregma) were selected
and cell counting was performed from 5 subsequent slices (distance 100
µm) from 4 different animals.
Apoptosis measurement
Apoptotic neurons in the ischemic hemisphere 24 h after tMCAO were
visualized by TUNEL on cryo-embedded slices. Brain slices (10 µm
thickness) were ﬁxed in acetone for 10min and blocked for 1 h in 5%
BSA in PBS containing 1% Goat Serum and 0.3% Triton to prevent
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nonspeciﬁc binding. A mouse antibody to NeuN (MAB377, Millipore, 1:1000
in PBS) was applied over night at 4 °C. Proteins were detected by 45min of
incubation with Dylight 488–conjugated goat antibody to mouse
secondary antibodies (polyclonal, ab96871, Abcam) at a dilution of 1:200
in 1% BSA in PBS. TUNEL positive cells were stained using the in situ cell
death detection kit TMR red (Roche 12 156 792 910) following the manual
instructions. Negative controls included omission of primary or secondary
antibody and gave no signals (not shown).
Western blot analysis
Brains were extracted from sacriﬁced stroke animals and classiﬁed as
ipsilateral and contralateral. These were fast-frozen in liquid nitrogen, then
stored at −80 °C until the time of analysis. Snap-frozen brains were
crunched in liquid nitrogen and the brain powder was transferred into an
eppendorf tube. Then hot Laemmli buffer (Bio-Rad, Veenendaal, The
Netherlands), pre-heated at 95 °C and containing 5% β-mercaptoethanol,
was added and the powder was lysed and denaturated for 10min at 65 °C.
Ultrasounds (Hielscher, Teltow, Germany) were used to homogenize the
samples and then they were centrifuged at 12,000×g for 15 min at 4 °C.
The supernatant was collected and stored at −80 °C. The total protein
concentration was measured in the tissue supernatant by using the RC DC
assay (Bio-Rad, Veenendaal, The Netherlands). Brain lysates were separated
on a NuPAGE Novex 10% Bis–Tris Midi Gel 1.0 mm× 26 well, (Novex Life
Technologies, Bleiswijk, The Netherlands) with the XCell SureLock Midi-Cell
running tank (Life Technologies, Bleiswijk, The Netherlands). According to
the invitrogen protocol MES running buffer was used (Life Technologies,
Bleiswijk, The Netherlands).15 µg protein per well were loaded and
laemmli-buffer containing plus 5% β-mercaptoethanol was used to adjust
the volume and 0.3 µl protein marker were applied (LI-COR IRDye protein
molecular weight marker, Licor Westburg, Leusden, The Netherlands).
Proteins were transferred to nitrocellulose membranes using NuPAGE Iblot
Gel Transfer Stacks Nitrocellulose (Novex Life Technologies, Bleiswijk, The
Netherlands) on the iBlot Gel Transfer Device (Life Technologies, Bleiswijk,
The Netherlands). The blot was stained with Ponceau S (Sigma Aldrich,
Zwijndrecht, The Netherlands) to check for complete protein transfer. Non-
speciﬁc reactivity was blocked by incubating the membranes for 1 h at
room temperature with blocking buffer, 1 part Odyssey buffer (Licor
Westburg, Leusden, The Netherlands) and 1 part PBS (Merck Chemicals,
Amsterdam, The Netherlands). Hybridization also took place in Odyssey-
PBS Blocking Buffer. The membranes were incubated with primary
antibody overnight at 4 °C with a self-made polyclonal rabbit sGC-α1
antibody (dilution 1:2000) or with a polyclonal rabbit sGC-β1 antibody
(dilution 1:2000). After three washing steps with PBS containing 0.1%
Tween-20 (Merck Chemicals, Amsterdam, The Netherlands), the mem-
branes were incubated with the secondary antibody for 1 h at room
temperature with the secondary antibody (1:25,000 dilution, donkey anti
rabbit CW800). Then the membranes were washed again 3 times with PBS-
0.1%T and three times with PBS. Reactive proteins were visualized using a
near-infrared imager (Oddyssey detection system, Licor Westburg,
Leusden, The Netherlands) and the protein levels were determined by
densitometric analysis of the speciﬁc protein bands (Image J). GAPDH
(Millipore, Merck Chemicals, Amsterdam, The Netherlands) was used as an
internal control. Actin or GAPDH served as loading control for all Western
blot experiments. After normalization to loading control, sGCα1 and b1
protein data were expressed as mean fold change relative to the
concentration in healthy brain tissue, which was set to 1.
PCR studies
Total RNA was prepared with a Miccra D-8 power homogenizer (ART) using
the TRIzol reagent® (Invitrogen) and was quantiﬁed spectrophotometri-
cally. Then, 1 µg of total RNA were reversely transcribed with the TaqMan®
Reverse Transcription Reagents (Applied Biosystems) according to the
manufacturer’s protocol using random hexamers. Relative gene expression
levels of interleukin(Il)-1ß (assay ID: Mm 00434228_m1, Applied Biosys-
tems) and tumor necrosis factor(Tnf)α (assay ID: Mm 00443258_m1,
Applied Biosystems) were quantiﬁed with the ﬂuorescent TaqMan®
technology. Gapdh (TaqMan® Predeveloped Assay Reagents for gene
expression, part number: 4352339E, Applied Biosystems) was used as an
endogenous control to normalize the amount of sample RNA. The PCR was
performed with equal amounts of cDNA in the StepOnePlusTM Real-Time
PCR System (Applied Biosystems) using the TaqMan® Universal 2× PCR
Master Mix (Applied Biosystems). Reactions (total volume 12.5 µl) were
incubated at 50 °C for 2 min, at 95 °C for 10min followed by 40 cycles of 15
s at 95 °C and 1min at 60 °C. Water controls were included to ensure
speciﬁcity. Each sample was measured in triplicate and data points were
examined for integrity by analysis of the ampliﬁcation plot. The
comparative Ct method was used for relative quantiﬁcation of gene
expression.
Rat hippocampal slice experiments
MTT (3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolim bromide) from Sigma
(Madrid, Spain), KT5823 from Tocris (Biogen Cientíﬁca, Madrid, Spain) and
BAY60-2770 as well as BAY58-2776 from Maastricht University (The
Netherlands). Adult male Sprague-Dawley rats (275–325 g) from a colony
of our animal quarters were used. Experimental procedures were approved
by the institutional Ethics Committee of Universidad Autónoma de Madrid
(Spain) in accordance with the European Guidelines for the use and care of
animals for research. All efforts were made in order to reduce animal
suffering and decrease the number of animals used. For hippocampal
slices preparation and induction of oxygen and glucose deprivation (OGD),
animals were decapitated under sodium pentobarbital anesthesia (60mg/
kg, i.p.), the brains were removed and located into ice-cold Krebs
bicarbonate dissection buffer (pH 7.4) composed of: NaCl 120mM, KCl 2
mM, NaHCO3 26mM, KH2PO4 1.18mM, MgSO4 10mM, CaCl 0.5 mM,
glucose 11mM and sucrose 200mM. The solutions were pre-bubbled with
95% O2/5% CO2 for not less than 30min before starting the experiment.
Thereafter, hippocampi were dissected and immersed in cold, oxygenated
dissection buffer before sectioning in transverse slices of 250 µM using a
McIlwain Tissue Chopper. Attempting to stabilize tissue after slicing
trauma, slices were transferred to sucrose-free dissection buffer, bubbled
with 95% O2/5% CO2, during 45min at 34 °C. Then, control group slices
were incubated 15min in a Krebs solution, containing (in mM): NaCl 120,
KCl 2, NaHCO3 26, CaCl 2, KH2PO4 1.18, MgSO4 1.19 and glucose 11mM,
which was equilibrated with 95% O2/5% CO2. Slices subjected to oxygen
and glucose deprivation were incubated in a Krebs buffer pre-bubbled
with 95% N2/5% CO2, where 2-deoxyglucose replaced glucose. OGD period
was followed by 120min of reoxygenation at 37 °C where slices were
returned back to an oxygenated Krebs solution containing glucose. During
the reoxygenation period, slices were treated with different concentrations
of BAY60-2770 or BAY58-2667. KT-5823 was used as an inhibitor of PKG.
Cellular viability was quantiﬁed by their ability to reduce MTT.60 After the
reoxygenation period, slices were incubated with MTT (0.5 mg/ml) in Krebs
bicarbonate solution for 40min at 37 °C. Cell active dehydrogenases can
cleave the tetrazolium ring of MTT in order to generate a precipitated
formazan. The formazan produced was solubilized by adding 200 µl
dimethyl sulfoxide (DMSO), giving rise to a colored compound whose
optical density was measured in an ELISA microplate reader at 540 nm.
Absorbance values obtained in control slices were taken as 100% viability.
Statistical analysis
All results obtained from stroke brains were analyzed using the GraphPad
Prism 5.0 software (GraphPad Software Inc., San Diego, CA, USA). Data were
expressed as the means ± standard error of the mean of separate
experiments (n = 4). Statistical comparisons between groups were per-
formed using one-way ANOVA, followed by a two-tailed unpaired
Student's t test (for sGC alpha1 subunit). Differences between two
treatments were considered signiﬁcant at P < 0.05. All results were
expressed as mean ± SEM except for ordinal functional outcome scales
that were depicted as scatter plots. Numbers of animals (N = 10) necessary
to detect a standardized effect size on infarct volumes≥ 0.2 (vehicle
treated control mice vs. BAY60-2770 treated mice) were determined via a
priori sample size calculation with the following assumptions: α = 0.05, ß =
0.2, mean, 20% SD of the mean (GraphPad Stat Mate 2.0; GraphPad
Software). Data were tested for Gaussian distribution with the D’Agostino
and Pearson omnibus normality test and then analyzed by one-way
analysis of variance (ANOVA) with posthoc Bonferroni adjustment for P
values. If only 2 groups were compared, unpaired, two-tailed Student's t
test was applied. Nonparametric functional outcome scores were
compared by Kruskal–Wallis test with posthoc Dunn multiple comparison
test. For comparison of survival curves the log-rank test was used. P values
< 0.05 were considered statistically signiﬁcant.
Data availability
Experimental data from the cGMP-related cluster within the human
diseasome are available in the supplemental tables S1,S2A–D and S3 from
the authors. Relevant experimental data are available from the authors.
Diseasome cluster-based drug repurposing
F Langhauser et al.
11
Published in partnership with the Systems Biology Institute npj Systems Biology and Applications (2018)  8 
ACKNOWLEDGEMENTS
This work was supported by an ERC Advanced Investigator Grant (294683 RadMed to
H.H.H.W.S.), the Deutsche Forschungsgemeinschaft (to C.K.), and the Spanish Ministry
of Economy and Competence (Ref SAF2015-63935R to M.G.L.).
AUTHOR CONTRIBUTIONS
F.L. conducted all in vivo experiments; A.I.C. conducted all in vitro experiments; V.T.D.
performed sGC expression and activity assays; E.M.G., J.M., H.H.W.S. and A.L.B.
contributed to system biology studies; E.V.G., P.K., E.G. helped with study design and
data analysis; E.M.G., J.M., M.G., A.I.C., C.K., and H.H.H.W.S. designed experiments,
wrote and edited ﬁgures and manuscript.
ADDITIONAL INFORMATION
Supplementary information accompanies the paper on the npj Systems Biology and
Applications website (https://doi.org/10.1038/s41540-017-0039-7).
Competing interests: H.H.H.W.S. receive a research grant from Bayer Healthcare, the
patent owner of BAY58-2667 and BAY60-2770. The remaining authors declare no
competing ﬁnancial interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. O’Collins, V. E. et al. 1,026 experimental treatments in acute stroke. Ann. Neurol.
59, 467–477 (2006).
2. Goh, K.-I. et al. The human disease network. Proc. Natl. Acad. Sci. USA 104,
8685–8690 (2007).
3. Menche, J. et al. Disease networks. Uncovering disease–disease relationships
through the incomplete interactome. Science 347, 1257601–1257601 (2015).
4. Zhou, X., Menche, J., Barabási, A.-L. & Sharma, A. Human symptoms–disease
network. Nat. Commun. 5, 4212 (2014).
5. Oettrich, J. M. et al. Clinical relevance of cyclic GMP modulators: a translational
success story of network pharmacology. Clin. Pharmacol. Ther. 99, 360–362
(2016).
6. Erdmann, J. et al. Dysfunctional nitric oxide signalling increases risk of myocardial
infarction. Nature 504, 432–436 (2013).
7. Atochin, D. N. et al. Soluble guanylate cyclase alpha1beta1 limits stroke size and
attenuates neurological injury. Stroke 41, 1815–1819 (2010).
8. Kemp-Harper, B. & Schmidt, H. H. H. W. cGMP in the vasculature. Handb. Exp.
Pharmacol. 191, 447–467 (2009).
9. Parker, J. O. Nitrates and angina pectoris. Am. J. Cardiol. 72, 3C–6C (1993).
10. Khot, U. N. et al. Nitroprusside in critically ill patients with left ventricular dys-
function and aortic stenosis. N. Engl. J. Med. 348, 1756–1763 (2003).
11. Ghofrani, H. A. et al. Riociguat for the treatment of pulmonary arterial hyper-
tension. N. Engl. J. Med. 369, 330–340 (2013).
12. Stasch, J.-P., Schlossmann, J. & Hocher, B. Renal effects of soluble guanylate
cyclase stimulators and activators: a review of the preclinical evidence. Curr. Opin.
Pharmacol. 21, 95–104 (2015).
13. Sharina, I. G. et al. Alpha1 soluble guanylyl cyclase (sGC) splice forms as
potential regulators of human sGC activity. J. Biol. Chem. 283, 15104–15113
(2008).
14. Guney, E., Menche, J., Vidal, M. & Barabási, A.-L. Network-based in silico drug
efﬁcacy screening. Nat. Commun. 7, 10331 (2016).
15. Wong, D., Dorovini-Zis, K. & Vincent, S. R. Cytokines, nitric oxide, and cGMP
modulate the permeability of an in vitro model of the human blood-brain barrier.
Exp. Neurol. 190, 446–455 (2004).
16. Kim, T. J., Lee, J. S., Hong, J. M. & Lim, Y. C. Intracerebral steal phenomenon: a
potential mechanism for contralateral stroke after carotid artery stenting. Neu-
rologist 18, 128–129 (2012).
17. Friebe, A. & Koesling, D. The function of NO-sensitive guanylyl cyclase: what we
can learn from genetic mouse models. Nitric Oxide 21, 149–156 (2009).
18. Semplicini, A. & Calò, L. Administering antihypertensive drugs after acute
ischemic stroke: timing is everything. CMAJ 172, 625–626 (2005).
19. Kleinschnitz, C. et al. NOS knockout or inhibition but not disrupting PSD-95-NOS
interaction protect against ischemic brain damage. J. Cereb. Blood Flow Metab.
0271678X16657094. https://doi.org/10.1177/0271678X16657094 (2016).
20. Ando, H. et al. Localization of mRNAs encoding alpha and beta subunits of
soluble guanylyl cyclase in the brain of rainbow trout: comparison with the
distribution of neuronal nitric oxide synthase. Brain Res. 1013, 13–29 (2004).
21. Nedvetsky, P. I., Kleinschnitz, C. & Schmidt, H. H. H. W. Regional distribution of
protein and activity of the nitric oxide receptor, soluble guanylyl cyclase, in rat
brain suggests multiple mechanisms of regulation. Brain Res. 950, 148–154
(2002).
22. Cote, G. J. et al. Hydrogen peroxide alters splicing of soluble guanylyl cyclase and
selectively modulates expression of splicing regulators in human cancer cells.
PLoS. ONE 7, e41099 (2012).
23. Meurer, S. et al. Nitric oxide-independent vasodilator rescues heme-oxidized
soluble guanylate cyclase from proteasomal degradation. Circ. Res. 105, 33–41
(2009).
24. Kumar, V. et al. Insights into BAY 60-2770 activation and S-nitrosylation-
dependent desensitization of soluble guanylyl cyclase via crystal structures of
homologous nostoc H-NOX domain complexes. Biochemistry 52, 3601–3608
(2013).
25. Lapp, H. et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemody-
namics in patients with acute decompensated heart failure. Circulation 119,
2781–2788 (2009).
26. Surapisitchat, J., Jeon, K.-I., Yan, C. & Beavo, J. A. Differential regulation of
endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ. Res.
101, 811–818 (2007).
27. Becker, L. C. Conditions for vasodilator-induced coronary steal in experimental
myocardial ischemia. Circulation 57, 1103–1110 (1978).
28. Nakano, T. et al. Delayed treatment with ADAMTS13 ameliorates cerebral
ischemic injury without hemorrhagic complication. Brain Res. 1624, 330–335
(2015).
29. Boutin, H. et al. Role of IL-1alpha and IL-1beta in ischemic brain damage. J.
Neurosci. 21, 5528–5534 (2001).
30. Hallenbeck, J. M. The many faces of tumor necrosis factor in stroke. Nat. Med. 8,
1363–1368 (2002).
31. Barone, F. C. et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain
injury. Stroke 28, 1233–1244 (1997).
32. Basu, A. et al. Interleukin-1 and the interleukin-1 type 1 receptor are essential for
the progressive neurodegeneration that ensues subsequent to a mild hypoxic/
ischemic injury. J. Cereb. Blood Flow. Metab. 25, 17–29 (2005).
33. Lambertsen, K. L., Biber, K. & Finsen, B. Inﬂammatory cytokines in experimental
and human stroke. J. Cereb. Blood Flow. Metab. 32, 1677–1698 (2012).
34. Lee, Y. et al. Therapeutically targeting neuroinﬂammation and microglia after
acute ischemic stroke. Biomed. Res. Int. 2014, 297241–297249 (2014).
35. Kleikers, P. W. M. et al. NADPH oxidases as a source of oxidative stress and
molecular target in ischemia/reperfusion injury. J. Mol. Med. 90, 1391–1406
(2012).
36. Lonze, B. E. & Ginty, D. D. Function and regulation of CREB family transcription
factors in the nervous system. Neuron 35, 605–623 (2002).
37. Paul, C., Stratil, C., Hofmann, F. & Kleppisch, T. cGMP-dependent protein kinase
type I promotes CREB/CRE-mediated gene expression in neurons of the lateral
amygdala. Neurosci. Lett. 473, 82–86 (2010).
38. Stasch, J.-P. et al. Targeting the heme-oxidized nitric oxide receptor for selective
vasodilatation of diseased blood vessels. J. Clin. Invest. 116, 2552–2561 (2006).
39. Evgenov, O. V. et al. NO-independent stimulators and activators of soluble gua-
nylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug. Discov. 5,
755–768 (2006).
40. Ohigashi, T., Brookins, J. & Fisher, J. W. Interaction of nitric oxide and cyclic
guanosine 3′,5′-monophosphate in erythropoietin production. J. Clin. Invest. 92,
1587–1591 (1993).
41. Fedorov, N. A., Ermil’chenko, G. V., Malykhina, I. S. & Borisov, B. N. Cyclic gua-
nosine-3′,5′-monophosphate–mediator of the action of the hormaone ery-
thropoietin. Dokl. Akad. Nauk. SSSR 233, 985–988 (1977).
42. Cerami, A., Brines, M., Ghezzi, P., Cerami, C. & Itri, L. M. Neuroprotective properties
of epoetin alfa. Nephrol. Dial. Transplant. 17 Suppl 1, 8–12 (2002).
43. Villa, P. et al. Reduced functional deﬁcits, neuroinﬂammation, and secondary
tissue damage after treatment of stroke by nonerythropoietic erythropoietin
derivatives. J. Cereb. Blood Flow. Metab. 27, 552–563 (2007).
44. Mengozzi, M. et al. Erythropoietin-induced changes in brain gene expression
reveal induction of synaptic plasticity genes in experimental stroke. Proc. Natl.
Acad. Sci. USA 109, 9617–9622 (2012).
45. Ehrenreich, H. et al. Recombinant human erythropoietin in the treatment of acute
ischemic stroke. Stroke 40, e647–e656 (2009).
46. Gheorghiade, M. et al. Soluble guanylate cyclase: a potential therapeutic target
for heart failure. Heart Fail. Rev. 18, 123–134 (2013).
47. Ghosh, A. et al. Soluble guanylate cyclase as an alternative target for broncho-
dilator therapy in asthma. Proc. Natl. Acad. Sci. USA 113, E2355–E2362 (2016).
48. Loscalzo, J., Kohane, I., Barabási, A.-L. Human disease classiﬁcation in the post-
genomic era: A complex systems approach to human pathobiology. Mol Syst Biol.
3, 124 (2007).
Diseasome cluster-based drug repurposing
F Langhauser et al.
12
npj Systems Biology and Applications (2018)  8 Published in partnership with the Systems Biology Institute
49. Ghiassian, S. D. et al. Endophenotype Network Models: Common Core of Com-
plex Diseases. Sci. Rep. 6, 27414 (2016).
50. Kleikers, P. W. et al. A combined pre-clinical meta-analysis and randomized
conﬁrmatory trial approach to improve data validity for therapeutic target vali-
dation. Sci. Rep. 5, 13428 (2015).
51. Hidalgo, C. A., Blumm, N., Barabási, A.-L. & Christakis, N. A. A dynamic network
approach for the study of human phenotypes. PLoS. Comput. Biol. 5, e1000353
(2009).
52. Kleinschnitz, C. et al. Post-stroke inhibition of induced NADPH oxidase type 4
prevents oxidative stress and neurodegeneration. PLoS. Biol. 8, e1000479 (2010).
53. Kleinschnitz, C. et al. Targeting coagulation factor XII provides protection from
pathological thrombosis in cerebral ischemia without interfering with hemos-
tasis. J. Exp. Med. 203, 513–518 (2006).
54. Pham, M. et al. Enhanced cortical reperfusion protects coagulation factor XII-
deﬁcient mice from ischemic stroke as revealed by high-ﬁeld MRI. Neuroimage
49, 2907–2914 (2010).
55. Stasch, J.-P. et al. NO- and haem-independent activation of soluble guanylyl
cyclase: molecular basis and cardiovascular implications of a new pharmacolo-
gical principle. Br. J. Pharmacol. 136, 773–783 (2002).
56. Brede, M. et al. α(2)-adrenoceptors do not mediate neuroprotection in acute
ischemic stroke in mice. J. Cereb. Blood Flow. Metab. 31, e1–e7 (2011).
57. Connolly, E. S., Winfree, C. J., Stern, D. M., Solomon, R. A. & Pinsky, D. J. Procedural
and strain-related variables signiﬁcantly affect outcome in a murine model of
focal cerebral ischemia. Neurosurgery 38, 523–31 (1996).
58. Bederson, J. B. et al. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for
detection and quantiﬁcation of experimental cerebral infarction in rats. Stroke 17,
1304–1308 (1986).
59. Moran, P. M., Higgins, L. S., Cordell, B. & Moser, P. C. Age-related learning deﬁcits
in transgenic mice expressing the 751-amino acid isoform of human beta-
amyloid precursor protein. Proc. Natl. Acad. Sci. 92, 5341–5345 (1995).
60. Denizot, F. & Lang, R. Rapid colorimetric assay for cell growth and survival.
Modiﬁcations to the tetrazolium dye procedure giving improved sensitivity and
reliability. J. Immunol. Methods 89, 271–277 (1986).
61. Chan, S. L. & Fiscus, R. R. Guanylyl cyclase inhibitors NS2028 and ODQ and protein
kinase G (PKG) inhibitor KT5823 trigger apoptotic DNA fragmentation in
immortalized uterine epithelial cells: anti-apoptotic effects of basal cGMP/PKG.
Mol. Hum. Reprod. 9, 775–783 (2003).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2018
Diseasome cluster-based drug repurposing
F Langhauser et al.
13
Published in partnership with the Systems Biology Institute npj Systems Biology and Applications (2018)  8 
